WO2025072797A3 - Immunogènes et compositions de vaccin contre le vih - Google Patents

Immunogènes et compositions de vaccin contre le vih Download PDF

Info

Publication number
WO2025072797A3
WO2025072797A3 PCT/US2024/049021 US2024049021W WO2025072797A3 WO 2025072797 A3 WO2025072797 A3 WO 2025072797A3 US 2024049021 W US2024049021 W US 2024049021W WO 2025072797 A3 WO2025072797 A3 WO 2025072797A3
Authority
WO
WIPO (PCT)
Prior art keywords
against hiv
hiv
immunogens
vaccine compositions
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/049021
Other languages
English (en)
Other versions
WO2025072797A2 (fr
Inventor
Morgane Marie ROLLAND
Eric LEWITUS
Hongjun BAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of WO2025072797A2 publication Critical patent/WO2025072797A2/fr
Publication of WO2025072797A3 publication Critical patent/WO2025072797A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des polypeptides Env du VIH-1 modifiés comprenant au moins une boucle hypervariable modifiée et des polynucléotides isolés comprenant une séquence nucléotidique qui code pour les polypeptides Env du VIH-1 modifiés. L'invention concerne également un vaccin ou des compositions immunogènes pour induire une réponse immunitaire chez un sujet contre le VIH, ainsi qu'un procédé d'induction d'une réponse immunitaire contre le VIH chez un sujet. L'invention concerne en outre des procédés d'identification d'un anticorps contre le VIH dans un échantillon.
PCT/US2024/049021 2023-09-27 2024-09-27 Immunogènes et compositions de vaccin contre le vih Pending WO2025072797A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363585686P 2023-09-27 2023-09-27
US63/585,686 2023-09-27

Publications (2)

Publication Number Publication Date
WO2025072797A2 WO2025072797A2 (fr) 2025-04-03
WO2025072797A3 true WO2025072797A3 (fr) 2025-05-15

Family

ID=95201347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/049021 Pending WO2025072797A2 (fr) 2023-09-27 2024-09-27 Immunogènes et compositions de vaccin contre le vih

Country Status (1)

Country Link
WO (1) WO2025072797A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028625A2 (fr) * 2003-09-17 2005-03-31 Duke University Immunogenes consensus/ancestraux
US20190194262A1 (en) * 2011-10-12 2019-06-27 University Of Washington, Center For Commercialization Engineered outer domain (eod) of hiv gp120 and mutants thereof
US20210277065A1 (en) * 2016-03-01 2021-09-09 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028625A2 (fr) * 2003-09-17 2005-03-31 Duke University Immunogenes consensus/ancestraux
US20190194262A1 (en) * 2011-10-12 2019-06-27 University Of Washington, Center For Commercialization Engineered outer domain (eod) of hiv gp120 and mutants thereof
US20210277065A1 (en) * 2016-03-01 2021-09-09 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies

Also Published As

Publication number Publication date
WO2025072797A2 (fr) 2025-04-03

Similar Documents

Publication Publication Date Title
CA2733898C (fr) Vaccin contre le vih polyvalent a base de variante m env
US9011875B2 (en) Human immunodeficiency virus type 1 clade M mosaic gag polypeptides
EP2371387A3 (fr) Antigènes consensus/ancestraux du VIH utilisés comme vaccins
WO2002020554A3 (fr) Peptides vih, antigenes, compositions de vaccin, coffret de dosage immunologique et procede permettant la detection d'anticorps induits par vih
MY145614A (en) Vaccine
WO2008140579A3 (fr) Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
Lema et al. HIV vaccines: a brief overview
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
WO2002032943A3 (fr) Modifications de env, gag, et pol de vih a pouvoir immunogene augmente aux fins d'immunisation genetique
Brand et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
Leung et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
Stuart et al. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea
WO2005111079A3 (fr) Immunogenes de vaccins vih et strategies d'immunisation, destines a eliciter des anticorps anti-hiv-1 a neutralisation large contre le domaine proximal de membrane de vih gp41
WO2025072797A3 (fr) Immunogènes et compositions de vaccin contre le vih
WO2023192971A3 (fr) Immunogènes et compositions vaccinales contre le vih
WO2001070262A3 (fr) Procede servant a generer des immunogenes elicitant des anticorps de neutralisation contre des zones de fusion active de proteines d'enveloppe de vih
WO2005027844A3 (fr) Compositions issues d'un vaccin adn et leurs procedes d'utilisation
Klein AIDS and HIV vaccines
WO2003029285A3 (fr) Identification de nouveaux epitopes cd8 des proteines du vih-1 presentant des proprietes therapeutiques et vaccinales contre les infection par le vih
WO2006091455A3 (fr) Echafaudages moleculaires destines a des immunogenes hiv-1
Ibuki et al. Protective effects against simian immunodeficiency virus agm (SIVagm) infection in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the SIVagm envelope gene
SIV Recombinant Modified Vaccinia Virus
WO2007070501A3 (fr) Procede de vaccination
BRUNET et al. Comparative Analysis of Humoral Immune Responses to HIV Type Envelope Glycoproteins in Mice Immunized with DNA Vaccine, Recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus Particles
Chege Pre-clinical assessment of novel candidate HIV-1 vaccines using the Chacma baboon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24873743

Country of ref document: EP

Kind code of ref document: A2